|
Volumn 34 Spec No 1, Issue , 2004, Pages 8-17
|
Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1;Efficacité clinique et tolérance de l'enfuvirtide (Fuzeon), nouvel antirétroviral inhibiteur de la pénétration intracellulaire du virus de l'immunodéficience humaine (VIH) de type 1.
a
a
HÔTEL DIEU
(France)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
ENFUVIRTIDE;
GLYCOPROTEIN GP 41;
HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;
PEPTIDE FRAGMENT;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
FEMALE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MALE;
MIDDLE AGED;
PATHOGENICITY;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
SUBCUTANEOUS DRUG ADMINISTRATION;
TREATMENT OUTCOME;
VIRUS LOAD;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTI-RETROVIRAL AGENTS;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIALS;
FEMALE;
HIV ENVELOPE PROTEIN GP41;
HIV FUSION INHIBITORS;
HIV INFECTIONS;
HIV-1;
HUMANS;
INJECTIONS, SUBCUTANEOUS;
MALE;
MIDDLE AGED;
PEPTIDE FRAGMENTS;
TREATMENT OUTCOME;
VIRAL LOAD;
|
EID: 14744276031
PISSN: 0399077X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (4)
|
References (0)
|